Abstract：
Extracellular vesicles (EVs) are promising next-generation therapeutics and drug delivery systems due to demonstrated safety and efficacy in preclinical models and early-stage clinical trials. There is an urgent need to address the immunogenicity of EVs (beyond the apparent lack of immunotoxicity) to advance clinical development. To date, few studies have assessed unintended immunological recognition of EVs. An in-depth understanding of EV-induced immunogenicity and clearance is necessary to develop effective therapeutic strategies, including approaches to mitigate immunological recognition when undesired. This article summarizes various factors involved in the potential immunogenicity of EVs and strategies to reduce immunological recognition for improved therapeutic benefit.
摘要：
由于在临床前模型和早期临床试验中证明的安全性和有效性，细胞外囊泡（EV）是有前途的下一代治疗剂和药物递送系统。迫切需要解决EV的免疫原性(除了明显缺乏免疫毒性之外)以推进临床开发。迄今为止,很少有研究评估了电动汽车的非预期免疫识别。深入了解EV诱导的免疫原性和清除对于制定有效的治疗策略是必要的。包括在不希望时减轻免疫识别的方法。本文总结了与EV潜在免疫原性有关的各种因素，以及降低免疫学识别以提高治疗效果的策略。
